|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.580 - 0.650|
|52 Week Range||0.210 - 1.560|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS, Feb. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and its wholly-owned subsidiary GB Sciences Louisiana, LLC. (GBSL) are pleased to announce the completion of a new agreement with Wellcana Group, LLC. (Wellcana) to work together on the previously announced initiative for the development of medical cannabis in Louisiana, a joint effort of the Louisiana State University AgCenter and GBSL, operating under the AgCenter's medical cannabis license, which is one of only two licenses granted by the State. The terms of the agreement provide that Wellcana will buy 15% of the newly-issued equity of GBSL for $3 million. Wellcana also has an option to purchase an additional 35% for an additional $7 million investment.
GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana
PHOENIX, Feb. 06, 2018-- GB Sciences, Inc., discusses 2017 achievements and 2018 operations expectations, on Stock Day Podcast with Everett Jolly.. “It is great to have GB Sciences Inc. back on the show,” ...
GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More
LAS VEGAS, Feb. 5, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn's disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually.
LAS VEGAS, Jan. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) welcomes Dr. Zoltan Mari, Section Head of the Nevada Movement Disorders Program and Lee Pascal Parkinson's Disease Scholar at Cleveland Clinic Lou Ruvo Center for Brain Health and a Clinical Professor of Neurology at the University of Nevada, Las Vegas, to its recently relaunched Scientific Advisory Board. Dr. Mari is a renowned expert of clinical research on Parkinson's disease and movement disorders, who is willing to offer his guidance on GB Sciences' Parkinson's disease therapy program.
GB Sciences Welcomes Dr. Zoltan Mari, A Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board
GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains
GB Sciences has developed controlled growth environments and methods to amplify the yield of important raw materials for its medical formulations. The Company has selected and nurtured several cannabis strains that are scoring some of the highest testing lab results seen in the Nevada market, according to the chemoprofile test results from DigiPath Labs. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations.
LAS VEGAS, Dec. 26, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) will be represented on the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco, on the 7th of January 2018. Dr. Andrea Small-Howard, Chief Science Officer, will serve on the Medical Cannabis in Neuroscience Panel on behalf of GB Sciences to discuss the opportunities and challenges of neuroscience product development in the cannabis biotech industry.
GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard, Has Been Invited to Join the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics ...
LAS VEGAS, Dec. 13, 2017 /PR Newswire/ -- GB Sciences, Inc. (GBLX) is proud to announce its development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, meaning that this potent strain may have significant medical benefits. The plant produced a THC-a content of 35.119%, as well as β-myrcene levels of 2.18% and β-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas. This strain is the result of an ongoing research project and is one of many tangible results of the coordination of the three operating units--- Life Sciences, Tissue Propagation, and Cultivation Labs. GB Sciences is a fully integrated cannabis company with three complementary operating units.
GB Sciences: Develops Extremely High THC Content Cannabis Strain With Maximized Terpene Levels To Increase Medical Benefits
Phoenix, AZ, Dec. 12, 2017-- Uptick Newswire is the sole producer of the Uptick Network“ Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of ...
SLTK products may be improving yield and production for cannabis cultivators, by as much as 2x the industry norm, according to one public company. As a result, revenue could be set to take off in 2018, ...
LAS VEGAS, Dec. 5, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) explains that 100% of the mother plants (a plant that in its vegetative state does not produce flowers but only branches and leaves) in their Las Vegas cultivation facility are now products of the GB Sciences tissue propagation initiative. In light of the popular belief that commercial tissue propagation is an 'urban myth' in the Cannabis world, this announcement is a true breakthrough. "We began the program in 2014 as a one-man project," said Dr. Ulrich Reimann-Philipp, Chief Botanist at GB Sciences.
GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light
LAS VEGAS, Nov. 15, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that it has exceeded the October gross revenue projection of $500K from the sale of premium flower by 2%. The GB Sciences cultivation facility has 180 active flower lights for plant cultivation and grows in a clean room-like environment.
Mr. Kevin Kuethe has been appointed COO of GB Sciences. The company is happy, the plants are happy, the customers are happy, and the shareholders should definitely be happy. LAS VEGAS, Nov. 13, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that it has met the October gross revenue projection of $500K from the sale of premium flower.
LAS VEGAS, Nov. 1, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences' intellectual property portfolio, consisting of three original patent applications, one licensed patent application, and one licensed approved patent. The Scientific Advisory Board will be tasked with efficiently managing GB Sciences' resources while creating and testing their proprietary cannabis-based formulas.
This production agreement guarantees GB Sciences a set royalty on every gram produced and sold. LAS VEGAS, Oct. 30, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and Cura Cannabis Solutions (Cura) have executed a production agreement to produce high quality cannabis oils and related products utilizing the GB Sciences production license operated by the GB Sciences' Cultivation Labs™.